1. Fig. 4. Effects of highly concentrated SFN provided as BSE in T2D patients.
Effects of highly concentrated SFN provided as BSE in T2D patients. (A) Association between HbA1c at the start of the study (baseline) and treatment-induced change in HbA1c (ΔHbA1c) after 12 weeks in all patients (n = 50 placebo and n = 47 BSE). (B) Box plots showing median, upper and lower quartiles, and maximum and minimum values of treatment-induced change in fasting blood glucose and HbA1c in obese patients with dysregulated T2D (n = 9 placebo and n = 8 BSE). Circle denotes outlier. (C) Association between serum concentration of SFN (after 12 weeks of treatment) and treatment-induced change in fasting blood glucose in obese patients with dysregulated T2D (n = 8 BSE). (D) Association between treatment-induced change in fasting blood glucose and plasma triglyceride concentrations at the start of the study in all patients (n = 50 placebo and n = 47 BSE). (E) Association between treatment-induced change in fasting blood glucose and HOMA-IR at the start of the study in patients with dysregulated T2D (n = 18 placebo and n = 19 BSE). (F) Association between treatment-induced change in HbA1c and fatty liver index at the start of the study in patients with dysregulated T2D (n = 18 placebo and n = 19 BSE). *P < 0.05.
Annika S. Axelsson et al., Sci Transl Med 2017;9:eaah4477
Published by AAAS